PubMed
Insulin-like growth factor-I and its binding proteins in sport and exercise medicine
Baxter RC. Endocr Rev. 2011
GH SecretagoguesResearch OnlyC
IGF-1 LR3
Long R3 IGF-1
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a recombinant analog of IGF-1 with an Arg3 substitution and a 13-amino acid N-terminal extension. These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs), resulting in a ~20–30 hour half-life (vs. 12–15 hours for native IGF-1) and significantly greater tissue exposure and anabolic potency. Research only; not FDA-approved.
Last reviewed . First published . By the PeptIQ team.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 5
- Research grade
- C
- Experience
- 99
- Activity
- 49
Overall check-ins
Trackers & reports
Overview
About IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a recombinant analog of IGF-1 with an Arg3 substitution and a 13-amino acid N-terminal extension. These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs), resulting in a ~20–30 hour half-life (vs. 12–15 hours for native IGF-1) and significantly greater tissue exposure and anabolic potency. Research only; not FDA-approved.
- Category
- GH Secretagogues
- Regulatory status
- Research Only
- Also known as
- Long R3 IGF-1
- Self-reports
- 30
Community
What 30 users report
30 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
171
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
5
Self-reported dose per injection
Median bucket: 50–100 mcg · Most common: 10–25 mcg
Reports span 0–200 mcg
0–10
1
10–25
60
25–50
1
50–100
53
100–200
56
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 96% said they felt similar to their last entry, 4% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 153 days · Based on 28 repeat reporters
Research
Sources (4)
- Wiki study page →Source
- Wiki study page →Source
ClinicalTrials.gov
IGF-1 LR3 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice
Engel MG, Narayan S, Cui MH, et al. Journal of Alzheimer's disease : JAD. 2025
- Wiki study page →Source
PubMed
Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration
Yavuz E, Sağır MS, Ercan A, et al. International journal of biological macromolecules. 2025
Tools
Explore more
Explore
More ways to learn about IGF-1 LR3 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about IGF-1 LR3?
This page summarizes 30 anonymized self-reports from PeptIQ users who track IGF-1 LR3, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for IGF-1 LR3?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for IGF-1 LR3?
4 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is IGF-1 LR3 safe to use?
This wiki does not assess safety or recommend use. IGF-1 LR3 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of IGF-1 LR3?
This wiki summarizes observational community reports and linked citations for IGF-1 LR3. It does not assert therapeutic benefits. See the sources list on this page and the educational profile for IGF-1 LR3 for study-level context — not medical advice.
What is the legal status of IGF-1 LR3?
IGF-1 LR3 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of IGF-1 LR3?
Safety data quality for IGF-1 LR3 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on IGF-1 LR3?
This page links 4 sources for IGF-1 LR3. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.